Allogene Therapeutics, Inc. (ALLO) Total liabilities 2019–2025
Allogene Therapeutics, Inc. (ALLO) total liabilities at each fiscal year-end, per SEC filings.
$123.4MFY2025 · since FY2019: $88.8M → $123.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $123.4M | -2.5% |
| FY2024 | $126.5M | -3.1% |
| FY2023 | $130.6M | -15.6% |
| FY2022 | $154.7M | +23.1% |
| FY2021 | $125.6M | -15.2% |
| FY2020 | $148.2M | +66.9% |
| FY2019 | $88.8M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ALLO financial trends
ALLO RevenueALLO Net incomeALLO Net marginALLO Gross profitALLO Gross marginALLO Operating incomeALLO Operating marginALLO Operating cash flowALLO Free cash flowALLO Capital expendituresALLO Return on equityALLO Stock buybacksALLO Dividends paidALLO Total assetsALLO Shareholders’ equityALLO overview →